Takeda Oveporexton Shows Broad Benefits in Narcolepsy
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 15, 2026 Takeda has unveiled new pivotal Phase 3 data demonstrating that oveporexton...
Biopharmaceuticals
Advertisement
Gilead’s Once-Weekly Yeztugo Accepted by FDA for HIV Prevention Review
FOSTER CITY, Calif., June 16, 2026 Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has...
Halia Therapeutics Secures FDA Fast Track for Ofirnoflast
LEHI, Utah, June 15, 2026 Halia Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted...
Halozyme Reaffirms Long-Term Royalty Growth Despite Proposed Medicare Pricing Changes
SAN DIEGO, June 15, 2026 Halozyme Therapeutics, Inc. has confirmed that it expects zero to minimal impact on royalty...
Akeso Wins NMPA Approval for Gumokimab in Plaque Psoriasis
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
Advertisements
Zai Lab Secures China Approval for TIVDAK in Cervical Cancer
SHANGHAI, China & CAMBRIDGE, Massachusetts, USA – June 9, 2026 Zai Lab has received approval from China’s National Medical...
AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results
GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...
Kashiv BioSciences Moves Closer to Launching XOLAIR Biosimilar in Canada
PISCATAWAY, N.J., June 4, 2026 Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by...
Chiesi Wins EU Approval for Pediatric LOJUXTA Use
PARMA, Italy, June 5, 2026 Chiesi Global Rare Diseases has announced a major regulatory milestone following the European Commission’s...
Innovent’s IBI343 Shows Strong Efficacy in Phase III Study, Eyes Regulatory Approval
SAN FRANCISCO and SUZHOU, China, June 4, 2026 Innovent Biologics has announced a major breakthrough in precision oncology as...
Advertisement
